JAMA by Petersen, Lyle R. et al.
West Nile Virus: Review of the Literature
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Abstract
IMPORTANCE—Since its introduction in North America in 1999,West Nile virus has produced 
the 3 largest arboviral neuroinvasive disease outbreaks ever recorded in the United States.
OBJECTIVE—To review the ecology, virology, epidemiology, clinical characteristics, diagnosis, 
prevention, and control of West Nile virus, with an emphasis on North America.
EVIDENCE REVIEW—PubMed electronic database was searched through February 5, 2013. 
United States national surveillance data were gathered from the Centers for Disease Control and 
Prevention.
FINDINGS—West Nile virus is now endemic throughout the contiguous United States, with 16 
196 human neuroinvasive disease cases and 1549 deaths reported since 1999. More than 780 000 
illnesses have likely occurred. To date, incidence is highest in the Midwest from mid-July to early 
September. West Nile fever develops in approximately 25% of those infected, varies greatly in 
clinical severity, and symptoms may be prolonged. Neuroinvasive disease (meningitis, 
encephalitis, acute flaccid paralysis) develops in less than 1% but carries a fatality rate of 
approximately 10%. Encephalitis has a highly variable clinical course but often is associated with 
considerable long-term morbidity. Approximately two-thirds of those with paralysis remain with 
significant weakness in affected limbs. Diagnosis usually rests on detection of IgM antibody in 
serum or cerebrospinal fluid. Treatment is supportive; no licensed human vaccine exists. 
Prevention uses an integrated pest management approach, which focuses on surveillance, 
elimination of mosquito breeding sites, and larval and adult mosquito management using 
pesticides to keep mosquito populations low. During outbreaks or impending outbreaks, emphasis 
shifts to aggressive adult mosquito control to reduce the abundance of infected, biting mosquitoes. 
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Pesticide exposure and adverse human health events following adult mosquito control operations 
for West Nile virus appear negligible.
CONCLUSIONS AND RELEVANCE—In North America, West Nile virus has and will remain 
a formidable clinical and public health problem for years to come.
West Nile virus has become endemic in all 48 contiguous United States as well as all 
Canadian provinces since its discovery in North America in New York City in1999.1 It has 
produced the 3 largest arboviral neuroinvasive disease (encephalitis, meningitis, or acute 
flaccid paralysis) outbreaks ever recorded in the United States, with nearly 3000 cases of 
neuroinvasive disease recorded each year in 2002, 2003, and 2012.
Evidence Review
This review is intended to provide a general overview of West Nile virus to the practicing 
physician or public health practitioner. Relevant background information was obtained by 
searching the PubMed electronic database through February 5, 2013, using the search term 
West Nile virus. Surveillance data from patients with disease onset from 1999 through 2012 
and reported by May 15, 2013, were gathered from the national ArboNET surveillance 
system conducted by the Centers for Disease Control and Prevention.
Ecology
West Nile virus is maintained in a bird-mosquito-bird transmission cycle. Although West 
Nile virus has been detected in 65 different mosquito species and 326 bird species in the 
United States, only a few Culex mosquito species drive transmission of the virus in nature 
and subsequent spread to humans: Culex pipiens (northern house mosquito) in the northern 
half of the United States, the closely related species Cx quinquefasciatus (southern house 
mosquito) in the southern states, and Cx tarsalis in many areas of the plains and western 
states that overlap with the distribution of Cx pipiens and Cx quinquefasciatus. Numerous 
passerine birds (perching birds of the order Passeriformes) develop sufficient serum viremia 
to efficiently infect mosquitoes feeding upon them and thus are competent amplifier hosts.2 
A relatively small subset of the bird community may significantly influence transmission 
dynamics and certain passerine species such as the American robin (Turdus migratorius) are 
important amplifiers despite their low abundance relative to other West Nile virus–
susceptible birds.3 Humans are unlikely to infect mosquitoes because they only develop a 
low-level serum viremia4,5 and thus are considered dead-end hosts.
When conditions favor substantial viral amplification within the passerine-Culex 
transmission cycle, increasing numbers of infected mosquitoes present a human infection 
risk by mid to late summer. The complex and interrelated factors that promote viral 
amplification and hence human outbreaks are not well quantified and vary among the 
diverse ecological conditions present in North America. Warmer temperatures correlate with 
increased human incidence at national or regional (multistate) scales.6 Increased ambient 
temperature shortens the incubation time from infection to infectiousness in mosquitoes and 
increases viral transmission efficiency to birds, both critical factors for arboviral 
amplification.7,8 At smaller scales, urban and agricultural land covers,9 rural irrigated 
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landscapes,10 increased temperature,11 increased rainfall,12 decreased rainfall,12 and several 
socioeconomic factors such as housing age and community drainage patterns,13 per capita 
income,10 and density of poorly maintained swimming pools14 relate to higher incidence in 
some locations. Nevertheless, considerable challenges remain in predicting how, when, and 
where these factors will combine to produce the focal, intense outbreaks that now 
characterize West Nile virus ecology in the United States.
Virology and Pathogenesis
West Nile virus is 1 of more than 70 viruses of the family Flaviviridae of the genus 
Flavivirus. Serologically, West Nile virus is a member of the Japanese encephalitis 
serocomplex, which includes Japanese encephalitis virus and an endemic North American 
flavivirus, St Louis encephalitis virus. West Nile viruses can be designated into at least 5 
phylogenetic lineages.15 Only lineage 1 and 2 West Nile viruses have been associated with 
significant outbreaks in humans.
Lineage 1 can be further subdivided into 3 sublineages: isolates from the western 
hemisphere, Africa, the Middle East, and Europe constitute lineage 1a; Kunjin virus from 
Australasia represents lineage 1b; and lineage 1c consists of viruses from India.16 The initial 
North American isolates (East Coast genotype) identified in 1999 in New York City have 
been most closely related to a lineage 1a West Nile virus isolated from Israel in 1998.17 
Since approximately 2002, the East Coast genotype has largely been displaced by a new 
genotype (WN02 genotype) encompassing several conserved amino acid substitutions that 
may have increased the efficiency and rapidity of viral transmission in North American 
mosquito vectors.7,18
Mosquito salivary components introduced at the site of infection in vertebrates modulate 
initial infection of target cells such as keratinocytes19 and skin-resident dendritic cells 
through several mechanisms including focalized suppression of immune effector cell 
trafficking to the site of inoculation.20 Infected dendritic cells or keratinocytes migrate to 
draining lymph nodes from which a serum viremia is generated that then relays infection to 
visceral organs and potentially to the central nervous system (Figure 1).
West Nile virus is capable of replicating and eliciting pathology in the brain (ie, 
neurovirulence); however, a critical prerequisite to generating neuroinvasive disease in 
humans is the virus’ capacity to gain access to the central nervous system (ie, 
neuroinvasiveness). Postulated West Nile virus neuroinvasive mechanisms include (1) direct 
viral crossing of the blood-brain barrier due to cytokine-mediated increased vascular 
permeability; (2) passage through the endothelium of the blood-brain barrier; (3) a Trojan 
horse mechanism in which infected tissue macrophages are trafficked across the blood-brain 
barrier; and (4) retrograde axonal transport of the virus to the central nervous system via 
infection of olfactory or peripheral neurons (Figure 2).21 Regardless of how the virus enters 
the central nervous system, murine models of infection have shown persistent viral 
replication in various tissues, including the central nervous system, suggesting a potential 
etiology for long-term neurological sequelae observed in patients with neuroinvasive 
disease.21
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Distribution and Human Disease Incidence
West Nile virus has an extensive distribution throughout Africa, the Middle East, southern 
Europe, western Russia, south western Asia, and Australia (Kunjin subtype of West Nile 
virus), which derives from its ability to infect numerous mosquito and bird species. Until the 
early 1990s, human outbreaks, mainly associated with mild febrile illnesses, were reported 
infrequently from Israel and Africa. Since then, new viral strains with likely African origin 
have increased human disease incidence in parts of Russia and southern and eastern Europe, 
with large outbreaks of increased clinical severity occurring in Romania, Russia, Israel, and 
Greece.15,22 In the western hemisphere, West Nile virus spread from its 1999 discovery 
location in New York City1 to the Pacific Coast by 200323,24 and Argentina by 2005.24 
Although West Nile virus now circulates in many countries in the western hemisphere, for 
unknown reasons only the United States and Canada have experienced substantial human 
disease incidence.24
Most patients with West Nile virus–related illnesses are unrecognized clinically. A follow-
up study of asymptomatic, viremic blood donors who subsequently developed West Nile 
fever showed that 38% sought medical care and 2% were hospitalized for symptoms 
attributable to the infection; however, only 5% of those seeking medical care were correctly 
diagnosed.4 Thus, incidence trends are best monitored by the incidence of neuroinvasive 
disease because reporting of these cases is comparatively complete. Nevertheless, even 
during a well-publicized outbreak, only 40% of patients with clinically compatible 
meningitis or encephalitis were tested for West Nile virus.25
A total of 16 196 patients with West Nile virus neuroinvasive disease with onsets from 1999 
through 2012 and 1549 deaths have been recorded in the United States. Although the 
number of patients with neuroinvasive disease fluctuates annually, some regions experience 
persistently higher incidence (Figure 3). Ninety-four percent of patients with West Nile virus 
infection have symptom onsets in July through September (Figure 4).23 Extrapolations from 
neuroinvasive disease case reporting in the United States suggest that through 2010 
approximately 3 million persons were infected, of whom 780 000 developed West Nile 
fever.26 In Canada, West Nile virus was first detected in southern Ontario in 2001 and by 
2009 the virus’ distribution had extended west ward to British Columbia. Through October 
2012, 975 patients with neuroinvasive disease have been reported in Canada.
Transmission to Humans
Mosquito bites account for nearly all human infections. West Nile virus can also be 
transmitted via transfused platelets, red blood cells, and fresh frozen plasma5 as well as 
through heart, liver, lung, and kidney transplants.27 Transmission via organ transplant has 
occurred from donors without detectable viremia, suggesting viral sequestration in organs 
shortly after viremia has cleared.
One possible transplacental transmission following a second trimester infection resulted in 
an infant with chorioretinitis, lissencephaly, and cerebral white matter loss. Fortunately, fetal 
abnormalities due to intrauterine infection are uncommon: none of 72 live infants born to 71 
women infected during pregnancy had malformations linked to West Nile viral infection or 
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had conclusive laboratory evidence of congenital infection.28 Nevertheless, 3 neonates born 
to women infected within 3 weeks’ prepartum developed symptomatic West Nile virus 
disease at or shortly after birth, indicating the possibility of intrauterine infection or 
infection at the time of delivery. Other rare or suspected modes of transmission include 
breast milk transmission, percutaneous or conjunctival exposure to laboratory workers, and 
by unknown means in patients undergoing dialysis and workers at a turkey breeder farm.24
Infection and Illness
It is not known what proportion of persons develop West Nile virus infection following an 
infected mosquito bite. Persons with a genetic defect in theOAS1 gene (HGNC 8086), which 
modulates host response to exogenous viral RNA, are more likely to have anti– West Nile 
virus antibodies than persons without this defect, suggesting that immune response function 
determines who becomes infected after exposure.29 Among persons who become infected, 
approximately 25% develop West Nile fever4 and 1 in 150 to 250 develops neuroinvasive 
disease.26,30 Risk factors for developing West Nile fever following infection are poorly 
defined. A follow-up study of asymptomatic, viremic blood donors indicated that increasing 
viral load and female sex, but not age, subsequently increased the risk of developing West 
Nile fever.4 A smaller follow-up study of viremic blood donors suggested that younger 
persons were more likely to develop West Nile fever.31 In contrast, advancing age 
profoundly increases the risk of neuroinvasive disease, particularly encephalitis.23,32 The 
risk may approach 1 in 50 among persons aged at least 65 years, a rate 16 times higher than 
that for persons aged 16 to 24 years.32 In addition, a history of cancer, diabetes, 
hypertension, alcohol abuse, renal disease, and chemokine receptor CCR5 deficiency as well 
as male sex may increase the risk of neuroinvasive disease.21,23,32–35 Persons infected 
through transplant of infected organs are at extreme risk of developing neuroinvasive 
disease27; however, conflicting data exist regarding risk among previous organ recipients 
infected via mosquito bite.36,37
Clinical Illness
The incubation period for clinical illness generally ranges from 2 to 14 days, but prolonged 
incubation periods of up to 21 days have been observed among immunocompromised 
patients.5,38 West Nile fever can range from a mild infirmity lasting a few days to a 
debilitating illness lasting weeks to months. Symptoms are of sudden onset and often 
include headache, malaise, fever, myalgia, chills, vomiting, rash, fatigue, and eye pain (Box 
1).4 Fever may be low-grade or absent. A rash, which often appears around the time of 
defervescence, tends to be morbilliform, maculopapular, and nonpruritic, and predominates 
over the torso and extremities, sparing the palms and soles.39
West Nile meningitis, similar to that of other viral meningitides, is characterized by abrupt 
onset of fever and headache along with meningeal signs and photophobia. Headache may be 
severe, and associated gastrointestinal disturbance may result in dehydration (Box 2).40 
West Nile encephalitis ranges in severity from a mild, self-limited confusional state to 
severe encephalopathy, coma, and death. Extrapyramidal disorders are frequently 
observed,41–44 and features of Parkinsonism may be seen.41,45 Patients with West Nile 
encephalitis frequently develop a coarse tremor, particularly in the upper extremities. The 
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tremor tends to be postural and may have a kinetic component.41,43,44 Myoclonus, 
predominantly of the upper extremities and facial muscles, may occur and may be present 
during sleep. Cerebellar ataxia, increased intracranial pressure, cerebral edema, and seizures 
have been described but are uncommon.43,44,46
West Nile virus–associated paralysis most commonly results from destruction of the anterior 
horn cells of the spinal cord.47–49 Asymmetric weakness usually develops rapidly within the 
first 48 hours after symptom onset, although patients with extensive spinal cord involvement 
develop a more symmetric dense quadriplegia. Central facial weakness, frequently bilateral, 
may occur.48 Respiratory failure requiring emergent endotracheal intubation may result 
from diaphragmatic and intercostal muscle paralysis.47 Sensory loss or numbness is 
generally absent though some patients experience intense pain in the affected limbs just 
before or during the onset of weakness.47 Other causes of weakness associated with West 
Nile virus infection include Guillain-Barre syndrome and other demyelinating neuropathies, 
motor axonopathy, axonal polyneuropathy, involvement of ventral spinal roots, myasthenia 
gravis, and brachial plexopathies.49
Other manifestations described in the setting of West Nile virus infection include mulitfocal 
choroiditis, vitritis, myocarditis, pancreatitis, fulminant hepatitis, rhabdomyolysis, stiff-
person syndrome, and autonomic instability.
Clinical Outcome
Full recovery is the norm for patients with uncomplicated West Nile fever or meningitis; 
however, initial symptoms, particularly extreme fatigue, may be prolonged.50 West Nile 
fever may precipitate death among persons of advanced age or with underlying medical 
conditions.51 Outcomes of West Nile encephalitis are variable and may not correlate with 
severity of initial illness. Patients hospitalized with West Nile virus encephalitis frequently 
require assistance with daily activities following acute care discharge42,52 and often report 
substantial functional and cognitive difficulties for up to a year following acute infection. 
Only 37% of patients in the 1999 New York City outbreak achieved full recovery at 1 year53 
and 53% of patients in Idaho reported symptoms lasting at least 6 months, mostly fatigue, 
muscle aches, and difficulties with memory and concentration.54
Although some studies have documented neurocognitive deficits on standardized testing for 
as long as 1 year after acute illness,55,56 others have failed to confirm this finding.40 
Nevertheless, self reported fatigue, somatic, and cognitive complaints lasting months or 
years are common among persons recovering from West Nile virus illness.53,57,58 
Neuropsychiatric symptoms, including depression, anxiety, and apathy, have been 
reported.41,59 One investigator reported West Nile virus RNA in urine in patients up to 7 
years following acute illness and implied an association with chronic renal failure60; 
however, 2 other studies failed to substantiate this finding.61,62
Among patients with acute flaccid paralysis due to poliomyelitis-like syndrome, roughly 
one-third recover strength to near baseline, one-third have some improvement, and one-third 
have little or no improvement.63 Little functional improvement has been documented 6 
months after onset.
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Case fatality rates among patients with neuroinvasive disease generally approximate 10%.23 
Advanced age is the most important risk factor for death, ranging from 0.8 % among those 
aged less than 40 years to 17% among those aged at least 70 years.23 Encephalitis with 
severe muscle weakness, changes in the level of consciousness, diabetes, cardiovascular 
disease, hepatitis C virus infection, and immunosuppression are possible risk factors for 
death.1,23,34 Patients discharged from the hospital following acute West Nile virus illness 
experience a 2- to 3-fold increase in long-term, all-cause mortality compared with age-
adjusted population norms, although not all of this increase may be attributable to West Nile 
virus.64
Diagnosis
Detection of IgM antibody in serum or cerebrospinal fluid (CSF) using the IgM antibody-
capture enzyme-linked immunosorbent assay (MAC-ELISA) forms the cornerstone of West 
Nile virus diagnosis in most clinical settings. Because IgM antibody does not cross the 
blood-brain barrier, its presence in CSF indicates CNS infection. At least 90% of patients 
with encephalitis or meningitis have demonstrable IgM antibodies in CSF within 8 days of 
symptom onset. The West Nile virus–specific IgM antibody may not be detected initially in 
serum or plasma; 1 study showed that only 58% of patients with West Nile fever had a 
positive MAC-ELISA result at clinical presentation.65 Nevertheless, MAC-ELISA testing of 
acute- and convalescent- phase sera will provide definitive diagnosis. Testing for IgG 
antibodies has no utility in the acute clinical diagnostic setting.
Recent vaccination with yellow fever or Japanese encephalitis vaccines or recent infection 
with a related flavivirus (eg, St Louis encephalitis or dengue) may produce a positive West 
Nile virus–IgM antibody test result. The plaque-reduction neutralization test can help 
distinguish serologic cross-reactions among the flaviviruses, but the test is only available in 
reference laboratories. In 1 study, 17% of patients had demonstrable West Nile virus–
specific IgM antibodies a year after initial infection; thus, persistent IgM antibody from a 
previous infection may be unrelated to current illness.66
Nucleic acid amplification testing has utility in certain clinical settings as an adjunct to 
MAC-ELISA. Among patients presenting with West Nile fever, 1 study showed that 45% of 
cases were identified with nucleic acid testing; 58% with serology, or 94% with a combined 
approach of these 2 methods.65 Nucleic acid amplification testing-may prove useful in 
immunocompromised patients when antibody development is delayed or absent and its use 
in blood donor screening in the United States and Canada has nearly eliminated the risk of 
West Nile virus transfusion transmission.
Total leukocyte counts in peripheral blood typically are normal or slightly elevated. 
Examination of CSF of patients with neuroinvasive disease shows normal glucose, elevated 
protein (generally <150 mg/dL) and moderate pleocytosis (generally <500 cells/µL) usually 
with a predominance of lymphocytes; however, neutrophils may predominate in early 
infection.67 Imaging studies are usually normal, but focal lesions in the pons, basil ganglia, 
thalamus, and anterior horns and enhancement of the leptomeninges, the periventricular 
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areas, or both are occasionally seen. These lesions may appear hyperintenseonT2-weighted 
magnetic resonance and fluid-attenuated inversion recovery images.68
Treatment and Prevention
Treatment of West Nile virus infection remains supportive. Several investigated therapeutic 
approaches include immune γ-globulin, West Nile virus–specific neutralizing monoclonal 
antibodies, corticosteroids, ribavirin, interferon α-2b, and antisense oligomers.69,70 No study 
has documented efficacy, in part due to difficulty in recruiting sufficient numbers of 
patients. Case reports or uncontrolled clinical series suggesting efficacy should be 
interpreted with extreme caution due to West Nile virus’s highly variable clinical course.
Novaccine is licensed for humans. Despite 4 licensed equine vaccines and promising 
preliminary results from several phase 1 and 2 human vaccine candidates, phase 3 efficacy 
trials have not been attempted due the unknown market potential of a West Nile virus 
vaccine and logistical difficulties in conducting phase 3 clinical trials for this sporadic and 
widely dispersed disease.69 Preliminary analysis suggested that universal West Nile virus 
vaccine coverage would not be cost-effective71; however, the cost-effectiveness of 
vaccination of specific target groups such as elderly individuals has not yet been established. 
Because humans are dead-end hosts, a human vaccination program would not influence viral 
amplification in nature.
West Nile virus prevention relies in part on methods to reduce the numbers of West Nile 
virus–infected mosquitoes. Community-based mosquito control programs using integrated 
pest management principles proactively identify the sources of vector mosquitoes and use 
several methods such as elimination of breeding sites, larviciding, and targeted adult 
mosquito control to prevent adult mosquito populations from achieving levels that increase 
human infection risk.
When increasing human case incidence or surveillance of vector mosquito populations 
indicates an impending human epidemic, the immediate goal is to reduce rapidly the number 
of infected adult mosquitoes by widespread ultra-low volume application of 
organophosphate or synthetic pyrethroid insecticides. Organophosphates irreversibly block 
the enzyme acetylcholinesterase; pyrethroids open sodium channels of neuronal membranes, 
paralyzing the mosquito, and are usually combined with piperonyl butoxide, preventing the 
mosquito’s microsomal oxidase enzymes from metabolizing pyrethroids.
Although the efficacy of these control measures is difficult to measure, strategically timed 
early-season control of adult mosquitoes in the Coachella Valley of California using ultra-
low volume insecticide applications decreased subsequent West Nile virus transmission.72 
In addition, aerial ultra-low volume insecticide application decreased infected mosquito 
abundance and reduced human- case incidence during a West Nile virus outbreak in the 
Sacramento area.73 Human health risks associated with ultra-low volume organophosphate 
or synthetic pyrethroid use appear negligible, largely because the timing of application and 
low volume of pesticide used result in minimal human exposure.74,75
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Insect repellent use has been associated with reduced West Nile virus risk.30 Unfortunately, 
few people report regular repellent use even during well-publicized outbreaks. 
Commercially available insect repellents containing DEET, IR3535, oil of lemon 
eucalyptus, and picaridin are registered by the US Environmental Protection Agency on the 
basis of their excellent safety profiles and proven efficacy in reducing or preventing 
mosquito biting. Many other commercially available unregistered products, such as those 
containing citronella oil, cedar oil, geraniumoil, peppermint oil, and soybeanoil, have 
unproven efficacy.
Future Perspectives
The resurgence of West Nile virus in 2012 after several years of decreasing incidence in the 
United States suggests that West Nile virus will continue to produce unpredictable local and 
regional outbreaks. These outbreaks are associated with considerable long- and short-term 
morbidity from West Nile virus neuroinvasive disease and West Nile fever, respectively. 
Thus, sustainable, community-based surveillance and vector management programs are 
critical, particularly in metropolitan areas with a history of West Nile virus and large human 
populations at risk. Community response plans must include provisions for rapidly 
implementing large-scale adult mosquito control interventions when surveillance indicates 
such measures are necessary. Further evaluation of target populations and cost-efficacy of a 
vaccine will help determine the need for continued human vaccine development. Practical 
pathways and paradigms for testing and approval of vaccines and therapeutics adapted to the 
sporadic outbreak nature of West Nile virus are required. These measures will not only help 
address the risks associated with West Nile virus but will add to our preparedness for all 
domestic and exotic mosquitoborne pathogens.
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Box 1
Characteristics of West Nile Fever
Abrupt onset, usually July through September
Occurs in approximately 25% of those infected by mosquito bite
All ages affected, but no strong age predilection
Symptoms present in more than 50% of patients4:
Headache, generalized weakness, morbilliform or maculopapular rash (often at time 
of defervescence), fever (often low grade), myalgia
Less common symptoms4:
Joint pain, chills, painful eyes, vomiting or diarrhea, lymphadenopathy
Diagnosis most readily made by detection of West Nile virus– specific IgM antibody in 
serum, although a convalescent-phase sample maybe required because the antibody often 
is not present at the time of clinical presentation
Treatment is supportive
Illness duration days to weeks, generally with complete recovery, although prolonged 
fatigue may occur
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Box 2
Characteristics of West Nile Neuroinvasive Disease
Abrupt onset, usually July through September
Occurs in less than 1% of those infected via mosquito bite
All ages affected, although very strong predilection with advancing age
Clinical Syndromes
Meningitis characterized by clinical signs of meningeal inflammation, including 
nuchal rigidity, Kernig or Brudzinski sign, or photophobia or phonophobia
Encephalitis characterized by depressed or altered level of consciousness, lethargy or 
personality change lasting more than 24 hours
Acute flaccid paralysis characterized by acute onset of limb weakness with marked 
progression over 48 hours, which is usually asymmetric, are flexic or hyporeflexic, 
and without sensory abnormalities. Four-fifths of persons with acute flaccid paralysis 
occur in conjunction with encephalitis or meningitis
May be commonly accompanied by other symptoms and signs35:
Nausea and vomiting, myalgia, chills, rash (less commonly reported than patients 
with West Nile fever), arthralgia, ataxia, visual disturbance, tremors, myoclonus, 
bulbar dysfunction (dysarthria, dysphagia)
Diagnosis most readily made by detection of West Nile virus–specific IgM antibody in 
cerebrospinal fluid or serum; in immunocompromised patients, development of IgM 
antibody may be delayed or absent, and nucleic acid amplification tests may be required
Cerebrospinal fluid generally shows normal glucose, elevated protein, pleocytosis (>5 
leukocytes/µL)
Treatment is supportive
Illness duration weeks to months; long-term functional and cognitive difficulties common 
in patients with encephalitis, paralysis, or both
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Figure 1. Schematic of Pathogenesis of West Nile Virus Infection
Following the bite of an infected mosquito, infection begins in keratinocytes and immune 
cells in the epidermis and spreads to draining lymph nodes. Viremia originating in the lymph 
nodes disseminates infection to peripheral organs.
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Figure 2. West Nile Virus Neuroinvasive Mechanisms
Potential mechanisms for neuroinvasion of West Nile virus include (1) direct infection of the 
vascular endothelium and subsequent entry to the central nervous system, (2) viral passage 
through the vascular endothelium due to disruption of the blood-brain barrier integrity by 
vasoactive cytokines, (3) a Trojan horse mechanism through which infected monocytes are 
trafficked into the central nervous system, or (4) retrograde axonal transport to the central 
nervous system following infection of peripheral neurons.
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Figure 3. 
Map of Average Annual Human Neuroinvasive Disease Incidence in the United States, 
1999–2012
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Figure 4. 
Cumulative Number of Human West Nile Virus Neuroinvasive Disease Cases by Week of 
Onset, 1999–2012
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